TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05896462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% povidone iodine
Description: The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
Study: NCT04057131

Intervention type: DRUG
Intervention: Firazyr
Description: Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
Study: NCT02012842

Intervention type: OTHER
Group type: OTHER
Intervention: Non surgical periodontal treatment
Description: Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal treatment
Description: Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
Study: NCT04589546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Description: Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
Study: NCT00981045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose (Venofer)
Description: 5 doses of 200 mg for a total cumulative dose of 1000 mg
Study: NCT03274141

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT00431028

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: slow delivery ciprofloxacin + triamcinolone
Description: 2 mg ciprofloxacin + 25mg triamcinolone
Study: NCT00220324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minisiston (SH D00342A)
Description: Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
Study: NCT04054973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 6000mg of L-arginine daily for 14 days
Study: NCT04024371

Intervention type: BEHAVIORAL
Intervention: Self-rating Questionnaires
Description: * Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)

Intervention type: BEHAVIORAL
Intervention: Self-rating Questionnaires
Description: * Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)

Intervention type: BEHAVIORAL
Intervention: Self-rating Questionnaires
Description: * Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)

Intervention type: BEHAVIORAL
Intervention: Measures of Reward processing/reinforcement learning
Description: * Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)
Study: NCT04054973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: 800mg of Kuvan daily for 14 days
Study: NCT03258840

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA Supplement
Description: EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA Placebo
Description: EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
Study: NCT02898727

Intervention type: OTHER
Group type: OTHER
Intervention: Local Therapy
Description: Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions.
Study: NCT04024371

Intervention type: BEHAVIORAL
Intervention: Measures of Reward processing/reinforcement learning
Description: * Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)

Intervention type: BEHAVIORAL
Intervention: Measures of Reward processing/reinforcement learning
Description: * Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)

Intervention type: BEHAVIORAL
Intervention: Additional Schizophrenia-specific Questionnaires and Interviews
Description: * Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)
Study: NCT02413554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Description: acetylcholine esterase inhibitor
Study: NCT03657524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: Speckle tracking echocardiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography
Description: Speckle tracking echocardiography
Study: NCT00595517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Description: Esomeprazole 20 mg once daily
Study: NCT03701841

Intervention type: DRUG
Intervention: PEG-rhG-CSF
Description: All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles

Intervention type: DRUG
Intervention: PEG-rhG-CSF
Description: All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
Study: NCT04231877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT02630225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention
Description: The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Agency Attention
Description: Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
Study: NCT00288067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT01433445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given 3 times a week, every other week in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Given twice daily in 28-day cycles.
Study: NCT03587883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols I
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control I
Description: Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols II
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control II
Description: Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
Study: NCT01943968

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Study: NCT01607060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulone
Description: Patients will receive lactulone to daily laxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulone
Description: Patients will receive lactulone to daily laxation
Study: NCT03804996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1801
Description: Intravenous infusion over 1 hour every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1801
Description: Intravenous infusion over 1 hour every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
Study: NCT03298620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric toothbrush

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Manual toothbrush
Study: NCT02471885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning
Description: each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10\^9/L; skip RIC if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
Study: NCT01596283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluid management
Description: The patient will receive standard fluid management

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goal directed fluid therapy with the Edwards EV1000 system
Description: This arm will have fluid therapy guided by the Edwards EV1000 system.
Study: NCT01614977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisoline
Description: Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
Study: NCT02682212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Description: Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
Study: NCT00857805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiotherapy
Description: Fifteen consecutive sessions
Study: NCT03855163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspection visits
Description: Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance workshops
Description: Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online risk assessment tool
Description: Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
Study: NCT05764226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
Description: One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
Study: NCT01486758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01743300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit juice
Description: The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
Study: NCT03240536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choosing Wisely form
Description: The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~1. Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~2. Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~3. Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management.
Study: NCT03020329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fu
Description: Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Description: Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.